BIO-key International, Inc. Logo

BIO-key International, Inc.

BKYI

(1.5)
Stock Price

0,87 USD

-256.54% ROA

-5377.77% ROE

-0.13x PER

Market Cap.

1.401.415,00 USD

-214.9% DER

0% Yield

-142.18% NPM

BIO-key International, Inc. Stock Analysis

BIO-key International, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

BIO-key International, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.45x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

3 DER

The stock maintains a fair debt to equity ratio (85%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

5 ROE

Negative ROE (-162.41%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

6 ROA

The stock's ROA (-98.99%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

BIO-key International, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

BIO-key International, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

BIO-key International, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

BIO-key International, Inc. Revenue
Year Revenue Growth
1996 32.000
1997 464.168 93.11%
1998 384.580 -20.69%
1999 157.970 -143.45%
2000 1 -15796900%
2001 0 0%
2002 155.399 100%
2003 524.101 70.35%
2004 5.558.231 90.57%
2005 14.226.095 60.93%
2006 15.193.625 6.37%
2007 9.988.456 -52.11%
2008 12.876.047 22.43%
2009 2.357.282 -446.22%
2010 3.520.408 33.04%
2011 3.508.804 -0.33%
2012 3.835.893 8.53%
2013 1.985.976 -93.15%
2014 4.005.856 50.42%
2015 5.261.225 23.86%
2016 2.975.756 -76.8%
2017 6.302.984 52.79%
2018 4.044.542 -55.84%
2019 2.267.528 -78.37%
2020 2.836.782 20.07%
2021 5.114.489 44.53%
2022 7.020.258 27.15%
2023 7.313.484 4.01%
2023 7.754.905 5.69%
2024 4.565.144 -69.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

BIO-key International, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 386.613
1997 563.045 31.34%
1998 1.570.033 64.14%
1999 856.692 -83.27%
2000 1.136.245 24.6%
2001 947.932 -19.87%
2002 1.084.513 12.59%
2003 1.037.330 -4.55%
2004 2.979.904 65.19%
2005 6.846.035 56.47%
2006 6.514.353 -5.09%
2007 4.994.799 -30.42%
2008 4.488.792 -11.27%
2009 927.241 -384.1%
2010 1.055.980 12.19%
2011 1.116.658 5.43%
2012 947.371 -17.87%
2013 1.344.070 29.51%
2014 1.626.136 17.35%
2015 1.556.025 -4.51%
2016 2.008.942 22.55%
2017 1.659.875 -21.03%
2018 1.415.401 -17.27%
2019 1.331.667 -6.29%
2020 1.396.436 4.64%
2021 2.355.056 40.7%
2022 3.252.236 27.59%
2023 2.234.744 -45.53%
2023 2.394.926 6.69%
2024 2.364.936 -1.27%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

BIO-key International, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1.880.102 100%
2016 0 0%
2017 0 0%
2018 5.333.906 100%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

BIO-key International, Inc. EBITDA
Year EBITDA Growth
1996 -771.776
1997 -2.682.644 71.23%
1998 -4.921.440 45.49%
1999 -2.816.994 -74.71%
2000 -2.851.808 1.22%
2001 -2.234.455 -27.63%
2002 -2.859.285 21.85%
2003 -2.714.046 -5.35%
2004 -5.889.557 53.92%
2005 -17.567.512 66.47%
2006 -566.265 -3002.35%
2007 -4.531.937 87.51%
2008 774.907 684.84%
2009 -2.110.155 136.72%
2010 -2.187.344 3.53%
2011 -1.285.380 -70.17%
2012 67.765 1996.82%
2013 -2.472.095 102.74%
2014 -1.970.309 -25.47%
2015 -1.638.734 -20.23%
2016 -4.150.348 60.52%
2017 -2.698.879 -53.78%
2018 -5.255.505 48.65%
2019 -6.562.050 19.91%
2020 -4.831.699 -35.81%
2021 -4.997.781 3.32%
2022 -8.366.336 40.26%
2023 -2.997.304 -179.13%
2023 -8.236.179 63.61%
2024 -6.160.240 -33.7%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

BIO-key International, Inc. Gross Profit
Year Gross Profit Growth
1996 17.125
1997 73.925 76.83%
1998 -669.968 111.03%
1999 191.164 450.47%
2000 137.304 -39.23%
2001 0 0%
2002 152.679 100%
2003 435.020 64.9%
2004 3.494.011 87.55%
2005 10.382.462 66.35%
2006 11.796.919 11.99%
2007 8.203.680 -43.8%
2008 11.140.906 26.36%
2009 1.853.047 -501.22%
2010 2.961.267 37.42%
2011 2.698.345 -9.74%
2012 3.264.160 17.33%
2013 1.598.948 -104.14%
2014 3.257.106 50.91%
2015 3.981.704 18.2%
2016 2.246.073 -77.27%
2017 -181.318 1338.75%
2018 -119.648 -51.54%
2019 -193.717 38.24%
2020 2.041.956 109.49%
2021 3.441.560 40.67%
2022 4.980.688 30.9%
2023 5.607.068 11.17%
2023 1.431.319 -291.74%
2024 3.516.056 59.29%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

BIO-key International, Inc. Net Profit
Year Net Profit Growth
1996 -823.488
1997 -2.593.814 68.25%
1998 -5.951.302 56.42%
1999 -3.428.357 -73.59%
2000 -3.130.453 -9.52%
2001 -2.283.774 -37.07%
2002 -4.019.974 43.19%
2003 -3.826.073 -5.07%
2004 -7.237.465 47.14%
2005 358.065 2121.27%
2006 -11.080.851 103.23%
2007 -1.057.224 -948.11%
2008 119.179 987.09%
2009 4.693.549 97.46%
2010 -306.789 1629.89%
2011 -1.897.606 83.83%
2012 3.267 58184.05%
2013 -2.582.151 100.13%
2014 -1.883.572 -37.09%
2015 -1.857.306 -1.41%
2016 -4.189.704 55.67%
2017 -4.275.338 2%
2018 -6.868.875 37.76%
2019 -14.652.981 53.12%
2020 -13.590.293 -7.82%
2021 -4.569.708 -197.4%
2022 -10.742.706 57.46%
2023 -2.996.364 -258.52%
2023 -8.521.837 64.84%
2024 -6.667.800 -27.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

BIO-key International, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 -16
1997 -71 77.46%
1998 -152 53.29%
1999 -79 -92.41%
2000 -63 -27.42%
2001 -40 -55%
2002 -58 31.03%
2003 -42 -41.46%
2004 -40 -5.13%
2005 -17 -129.41%
2006 -42 59.52%
2007 -3 -1300%
2008 -10 66.67%
2009 12 181.82%
2010 -1 0%
2011 -5 100%
2012 0 0%
2013 -5 100%
2014 -3 -66.67%
2015 -3 -50%
2016 -6 66.67%
2017 -5 -20%
2018 -5 -25%
2019 -148 97.3%
2020 -52 -184.62%
2021 -11 -420%
2022 -24 56.52%
2023 0 0%
2023 -15 100%
2024 -4 -275%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

BIO-key International, Inc. Free Cashflow
Year Free Cashflow Growth
1996 -726.874
1997 -2.816.701 74.19%
1998 -4.588.430 38.61%
1999 -2.202.468 -108.33%
2000 -1.723.323 -27.8%
2001 -1.925.725 10.51%
2002 -2.264.937 14.98%
2003 -2.923.688 22.53%
2004 -5.919.952 50.61%
2005 -4.727.899 -25.21%
2006 -3.779.810 -25.08%
2007 -2.210.428 -71%
2008 91.017 2528.59%
2009 -1.697.494 105.36%
2010 -322.830 -425.82%
2011 -579.315 44.27%
2012 65.552 983.75%
2013 -2.813.324 102.33%
2014 -2.521.560 -11.57%
2015 -15.563.452 83.8%
2016 -4.499.805 -245.87%
2017 -2.692.220 -67.14%
2018 -1.695.933 -58.75%
2019 -1.880.836 9.83%
2020 -4.985.676 62.28%
2021 -9.020.452 44.73%
2022 -6.311.074 -42.93%
2023 -3.794.456 -66.32%
2023 0 0%
2024 -1.420.617 100%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

BIO-key International, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 -683.593
1997 -2.653.301 74.24%
1998 -4.557.026 41.78%
1999 -2.200.030 -107.13%
2000 -1.723.323 -27.66%
2001 -1.925.725 10.51%
2002 -2.264.937 14.98%
2003 -2.857.145 20.73%
2004 -5.644.759 49.38%
2005 -4.513.497 -25.06%
2006 -3.551.455 -27.09%
2007 -2.161.217 -64.33%
2008 129.173 1773.12%
2009 -1.654.716 107.81%
2010 -312.930 -428.78%
2011 -523.111 40.18%
2012 65.552 898.01%
2013 -2.683.911 102.44%
2014 -2.502.927 -7.23%
2015 -15.560.088 83.91%
2016 -4.446.830 -249.91%
2017 -2.465.462 -80.36%
2018 -1.613.475 -52.8%
2019 -1.850.347 12.8%
2020 -4.950.108 62.62%
2021 -8.978.428 44.87%
2022 -6.229.034 -44.14%
2023 -3.793.456 -64.2%
2023 0 0%
2024 -1.420.617 100%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

BIO-key International, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 43.281
1997 163.400 73.51%
1998 31.404 -420.32%
1999 2.438 -1188.11%
2000 0 0%
2001 0 0%
2002 0 0%
2003 66.543 100%
2004 275.193 75.82%
2005 214.402 -28.35%
2006 228.355 6.11%
2007 49.211 -364.03%
2008 38.156 -28.97%
2009 42.778 10.8%
2010 9.900 -332.1%
2011 56.204 82.39%
2012 0 0%
2013 129.413 100%
2014 18.633 -594.54%
2015 3.364 -453.89%
2016 52.975 93.65%
2017 226.758 76.64%
2018 82.458 -175%
2019 30.489 -170.45%
2020 35.568 14.28%
2021 42.024 15.36%
2022 82.040 48.78%
2023 1.000 -8104%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

BIO-key International, Inc. Equity
Year Equity Growth
1996 -156.171
1997 3.641.683 104.29%
1998 -556.614 754.26%
1999 -1.683.862 66.94%
2000 -3.286.312 48.76%
2001 -3.896.999 15.67%
2002 -7.177.047 45.7%
2003 -9.135.989 21.44%
2004 10.621.398 186.01%
2005 9.307.728 -14.11%
2006 -2.743.360 439.28%
2007 -2.767.308 0.87%
2008 -3.081.949 10.21%
2009 1.108.232 378.1%
2010 569.335 -94.65%
2011 -1.271.091 144.79%
2012 -1.217.982 -4.36%
2013 1.050.935 215.9%
2014 759.061 -38.45%
2015 18.149.917 95.82%
2016 15.452.888 -17.45%
2017 13.753.295 -12.36%
2018 10.466.222 -31.41%
2019 -2.285.173 558.01%
2020 20.335.119 111.24%
2021 15.578.825 -30.53%
2022 7.060.018 -120.66%
2023 1.063.565 -563.81%
2023 3.327.417 68.04%
2024 -1.056.292 415.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

BIO-key International, Inc. Assets
Year Assets Growth
1996 405.263
1997 4.165.694 90.27%
1998 2.159.644 -92.89%
1999 360.724 -498.7%
2000 162.230 -122.35%
2001 763.310 78.75%
2002 257.634 -196.28%
2003 1.864.742 86.18%
2004 30.844.681 93.95%
2005 26.357.934 -17.02%
2006 20.464.541 -28.8%
2007 13.431.769 -52.36%
2008 11.247.990 -19.41%
2009 6.097.201 -84.48%
2010 5.315.170 -14.71%
2011 966.703 -449.82%
2012 1.136.841 14.97%
2013 2.701.405 57.92%
2014 2.067.449 -30.66%
2015 20.416.079 89.87%
2016 17.289.365 -18.08%
2017 16.078.822 -7.53%
2018 11.692.332 -37.52%
2019 2.496.698 -368.31%
2020 22.520.572 88.91%
2021 17.769.041 -26.74%
2022 11.913.405 -49.15%
2023 4.517.035 -163.74%
2023 9.832.658 54.06%
2024 4.798.996 -104.89%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

BIO-key International, Inc. Liabilities
Year Liabilities Growth
1996 561.434
1997 524.011 -7.14%
1998 2.716.258 80.71%
1999 2.044.586 -32.85%
2000 3.448.542 40.71%
2001 4.660.309 26%
2002 7.434.681 37.32%
2003 11.000.731 32.42%
2004 20.223.283 45.6%
2005 17.050.206 -18.61%
2006 23.207.901 26.53%
2007 16.199.077 -43.27%
2008 14.329.939 -13.04%
2009 4.988.969 -187.23%
2010 4.745.835 -5.12%
2011 2.237.794 -112.08%
2012 2.354.823 4.97%
2013 1.650.470 -42.68%
2014 1.308.388 -26.15%
2015 2.266.162 42.26%
2016 1.836.477 -23.4%
2017 2.325.527 21.03%
2018 1.226.110 -89.67%
2019 4.781.871 74.36%
2020 2.185.453 -118.8%
2021 2.190.216 0.22%
2022 4.853.387 54.87%
2023 3.453.470 -40.54%
2023 6.505.241 46.91%
2024 5.855.288 -11.1%

BIO-key International, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.65
Net Income per Share
-5.47
Price to Earning Ratio
-0.13x
Price To Sales Ratio
0.23x
POCF Ratio
-0.42
PFCF Ratio
-0.5
Price to Book Ratio
-1.11
EV to Sales
0.4
EV Over EBITDA
-0.27
EV to Operating CashFlow
-0.85
EV to FreeCashFlow
-0.85
Earnings Yield
-7.74
FreeCashFlow Yield
-2.02
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
8.84
Graham NetNet
-2.21

Income Statement Metrics

Net Income per Share
-5.47
Income Quality
0.31
ROE
-9.4
Return On Assets
-1.42
Return On Capital Employed
-17.5
Net Income per EBT
0.97
EBT Per Ebit
1.01
Ebit per Revenue
-1.45
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
0.32
Research & Developement to Revenue
0.39
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.15
Operating Profit Margin
-1.45
Pretax Profit Margin
-1.47
Net Profit Margin
-1.42

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.7
Free CashFlow per Share
-1.7
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.01
Return on Invested Capital
-7.6
Return on Tangible Assets
-2.57
Days Sales Outstanding
56
Days Payables Outstanding
103.89
Days of Inventory on Hand
29.23
Receivables Turnover
6.52
Payables Turnover
3.51
Inventory Turnover
12.49
Capex per Share
0

Balance Sheet

Cash per Share
0,76
Book Value per Share
-0,64
Tangible Book Value per Share
-1.39
Shareholders Equity per Share
-0.64
Interest Debt per Share
1.42
Debt to Equity
-2.15
Debt to Assets
0.47
Net Debt to EBITDA
-0.11
Current Ratio
0.54
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-1124306
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.26
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
436688
Debt to Market Cap
1.62

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

BIO-key International, Inc. Dividends
Year Dividends Growth
1997 0

BIO-key International, Inc. Profile

About BIO-key International, Inc.

BIO-key International, Inc. develops and markets fingerprint identification biometric technology and software solutions, and enterprise-ready identity access management solutions for commercial, government, and education customers in the United States and internationally. The company offers BIO-key PortalGuard and PortalGuard IDaaS solutions, a customer-controlled and neutral-by-design cloud-based identity platform that allows customers to integrate with any cloud or on-premises SaaS application, as well as windows device authentication through IAM platform. Its solutions enable its customers to secure their workforces and student populations; and make their partner networks more collaborative. In addition, it provides BIO-key VST and WEB-key products; and Civil and Large-Scale ID Infrastructure solutions that develops finger-based biometric technology. Further, it offers finger scanners for enterprise and consumer markets under SideSwipe, EcoID, and SidePass brand names. The company was formerly known as SAC Technologies and changed its name to BIO-key International, Inc. in 2002. BIO-key International, Inc. was founded in 1993 and is headquartered in Wall, New Jersey.

CEO
Mr. Michael W. DePasquale
Employee
43
Address
Building A
Wall, 07719

BIO-key International, Inc. Executives & BODs

BIO-key International, Inc. Executives & BODs
# Name Age
1 Ms. Cecilia C. Welch
Chief Financial Officer
70
2 Mr. James David Sullivan
Senior Vice President of Strategy & Compliance and Chief Legal Officer
70
3 Mr. Mark Cochran
President of PortalGuard
70
4 Ms. Mira K. LaCous
Chief Technology Officer
70
5 Mr. Akintunde Carlton Jeje
Managing Director of Africa
70
6 Mr. Alex Rocha
Managing Director of EMEA
70
7 Mr. Michael W. DePasquale
Chairman & Chief Executive Officer
70

BIO-key International, Inc. Competitors